The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2
The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2
Loss of function of the tumour suppressor gene p53 is a key event in most human cancers. Although usually occurring through mutation, in some tumour types this appears to be achieved via an indirect mechanism involving inappropriate expression of a functional inhibitor, mdm2, which binds to the transactivation domain of p53. This interaction offers an ideal potential target for novel cancer therapies. However, therapeutic specificity may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality, but the situation in adult cells is still unclear. Here we show that micro-injection of normal human fibroblasts with an antibody directed against the p53-binding domain of mdm2 induces expression of p53-responsive genes, and furthermore results in p53-dependent growth arrest. We conclude that normal cell proliferation can be dependent on negative regulation of p53 by mdm2, a finding which raises an important note of caution for mdm2-directed cancer therapies.
3317-3322
Blaydes, J.P,
e957f999-fd91-4f77-ad62-5b4ef069b15b
Wynford-Thomas, D.
e2abffc0-8c45-4681-b36b-6f1e0fba8ec7
25 June 1998
Blaydes, J.P,
e957f999-fd91-4f77-ad62-5b4ef069b15b
Wynford-Thomas, D.
e2abffc0-8c45-4681-b36b-6f1e0fba8ec7
Blaydes, J.P, and Wynford-Thomas, D.
(1998)
The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2.
Oncogene, 16 (25), .
Abstract
Loss of function of the tumour suppressor gene p53 is a key event in most human cancers. Although usually occurring through mutation, in some tumour types this appears to be achieved via an indirect mechanism involving inappropriate expression of a functional inhibitor, mdm2, which binds to the transactivation domain of p53. This interaction offers an ideal potential target for novel cancer therapies. However, therapeutic specificity may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality, but the situation in adult cells is still unclear. Here we show that micro-injection of normal human fibroblasts with an antibody directed against the p53-binding domain of mdm2 induces expression of p53-responsive genes, and furthermore results in p53-dependent growth arrest. We conclude that normal cell proliferation can be dependent on negative regulation of p53 by mdm2, a finding which raises an important note of caution for mdm2-directed cancer therapies.
This record has no associated files available for download.
More information
Published date: 25 June 1998
Identifiers
Local EPrints ID: 150571
URI: http://eprints.soton.ac.uk/id/eprint/150571
ISSN: 0950-9232
PURE UUID: 6e07933c-68f0-42ee-9995-a0f2809a9697
Catalogue record
Date deposited: 20 Jul 2010 14:05
Last modified: 23 Jul 2022 01:47
Export record
Contributors
Author:
D. Wynford-Thomas
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics